ABL1 and breast cancer: Progression to AP or BC was noted only in 3% of patients who achieved CCyR, and in none of patients who achieved major molecular response (MMR, < 0.1% BCR-ABL/control gene ratio on international scale) at 12 months of therapy.16 The patients treated with imatinib who had at 18 months a ≥ 3 log reduction in the level of BCR-ABL transcripts compared with a standardized baseline had a minimal risk of disease progression over the subsequent 12 months.17